311 related articles for article (PubMed ID: 22777336)
41. Adult Premenopausal Bone Health Related to Reproductive Characteristics-Population-Based Data from the Canadian Multicentre Osteoporosis Study (CaM
Goshtasebi A; Berger C; Barr SI; Kovacs CS; Towheed T; Davison KS; Prior JC
Int J Environ Res Public Health; 2018 May; 15(5):. PubMed ID: 29783670
[TBL] [Abstract][Full Text] [Related]
42. Variation in bone mineral density and fractures over 20 years among Canadians: a comparison of the Canadian Multicenter Osteoporosis Study and the Canadian Longitudinal Study on Aging.
Hassanabadi N; Berger C; Papaioannou A; Cheung AM; Rahme E; Leslie WD; Goltzman D; Morin SN
Osteoporos Int; 2023 Feb; 34(2):357-367. PubMed ID: 36449036
[TBL] [Abstract][Full Text] [Related]
43. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
44. Nonstandard Lumbar Region in Predicting Fracture Risk.
Alajlouni D; Bliuc D; Tran T; Pocock N; Nguyen TV; Eisman JA; Center JR
J Clin Densitom; 2018; 21(2):220-226. PubMed ID: 28689879
[TBL] [Abstract][Full Text] [Related]
45. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
46. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
47. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
48. Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos).
Lentle BC; Berger C; Probyn L; Brown JP; Langsetmo L; Fine B; Lian K; Shergill AK; Trollip J; Jackson S; Leslie WD; Prior JC; Kaiser SM; Hanley DA; Adachi JD; Towheed T; Davison KS; Cheung AM; Goltzman D;
J Bone Miner Res; 2018 Apr; 33(4):569-579. PubMed ID: 28722766
[TBL] [Abstract][Full Text] [Related]
49. Fracture prediction from bone mineral density in Japanese men and women.
Fujiwara S; Kasagi F; Masunari N; Naito K; Suzuki G; Fukunaga M
J Bone Miner Res; 2003 Aug; 18(8):1547-53. PubMed ID: 12929946
[TBL] [Abstract][Full Text] [Related]
50. Impact of spine-hip discordance on fracture risk assessment and treatment qualification in Canada: the Manitoba BMD registry.
Leslie WD; Morin SN; Lix LM; Binkley N
Arch Osteoporos; 2020 Jun; 15(1):85. PubMed ID: 32514615
[TBL] [Abstract][Full Text] [Related]
51. Quantitative ultrasound at the phalanxes discriminates osteoporotic women with vertebral but not with hip fracture.
Gnudi S; Ripamonti C
Ultrasound Med Biol; 2004 Mar; 30(3):357-61. PubMed ID: 15063517
[TBL] [Abstract][Full Text] [Related]
52. The degree of osteoporosis in patients with vertebral fracture and patients with hip fracture: relationship to incidence of vertebral fracture.
Takahashi M; Kushida K; Naitou K
J Bone Miner Metab; 1999; 17(3):187-94. PubMed ID: 10757678
[TBL] [Abstract][Full Text] [Related]
53. Effects of obesity and diabetes on rate of bone density loss.
Leslie WD; Morin SN; Majumdar SR; Lix LM
Osteoporos Int; 2018 Jan; 29(1):61-67. PubMed ID: 28917003
[TBL] [Abstract][Full Text] [Related]
54. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors.
Shin YH; Gong HS; Baek GH
J Clin Densitom; 2019; 22(2):236-242. PubMed ID: 30100220
[TBL] [Abstract][Full Text] [Related]
55. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment.
Leslie WD; Lix LM; Langsetmo L; Berger C; Goltzman D; Hanley DA; Adachi JD; Johansson H; Oden A; McCloskey E; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):817-27. PubMed ID: 21161509
[TBL] [Abstract][Full Text] [Related]
56. Femoral neck bone loss predicts fracture risk independent of baseline BMD.
Nguyen TV; Center JR; Eisman JA
J Bone Miner Res; 2005 Jul; 20(7):1195-201. PubMed ID: 15940372
[TBL] [Abstract][Full Text] [Related]
57. Differences in site-specific fracture risk among older women with discordant results for osteoporosis at hip and spine: study of osteoporotic fractures.
Fink HA; Harrison SL; Taylor BC; Cummings SR; Schousboe JT; Kuskowski MA; Stone KL; Ensrud KE;
J Clin Densitom; 2008; 11(2):250-9. PubMed ID: 18296090
[TBL] [Abstract][Full Text] [Related]
58. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
59. Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly.
Amoako AO; Jafilan L; Nasiri P; Pujalte GG
Curr Rheumatol Rev; 2016; 12(2):162-6. PubMed ID: 26496778
[TBL] [Abstract][Full Text] [Related]
60. Effect of long-term proton pump inhibitors on bone mineral density.
Romdhane H; Ayadi S; Elleuch N; Abdelghani K
Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
